When should oral acyclovir be started for herpes zoster in adults, especially those over 50 years old, immunocompromised, or with severe/disseminated disease?

When to Start Acyclovir for Shingles

Oral acyclovir 800 mg five times daily should be initiated within 72 hours of rash onset for optimal efficacy, though treatment started within 48 hours provides the greatest benefit in reducing acute pain, accelerating lesion healing, and preventing complications. 1, 2

Critical Timing Window

• The 72-hour window is the maximum timeframe for optimal antiviral efficacy, but studies demonstrate that treatment initiated within 48 hours produces significantly better outcomes than treatment started between 48-72 hours. 1, 2, 3

• Even when presentation occurs after 72 hours, treatment should still be initiated in high-risk populations (immunocompromised patients, those over 50 years, or patients with severe/disseminated disease) because some clinical benefit may still be realized. 4

• Viral shedding peaks in the first 24 hours after lesion onset, making early treatment particularly important for controlling viral replication and reducing complications. 4

Standard Oral Dosing Regimen

• Acyclovir 800 mg orally five times daily (every 4 hours while awake) for 7-10 days is the FDA-approved regimen for herpes zoster in immunocompetent adults. 5, 2

• Treatment must continue until all lesions have completely scabbed, not just for an arbitrary 7-day period—this is the key clinical endpoint. 4

• The five-times-daily dosing requirement may reduce adherence compared to valacyclovir (1000 mg three times daily) or famciclovir, though all three agents demonstrate similar efficacy when taken as prescribed. 6, 7

Special Populations Requiring Modified Approach

Adults Over 50 Years

• All patients ≥50 years with herpes zoster should receive antiviral therapy within 72 hours to reduce the duration and intensity of zoster-associated pain and accelerate healing. 6, 2

• This age group experiences significantly greater benefit from antiviral therapy, with valacyclovir demonstrating a median pain duration of 38 days versus 51 days with acyclovir in one large trial. 7

Immunocompromised Patients

• Severely immunocompromised patients (active chemotherapy, HIV, organ transplant recipients) require intravenous acyclovir 10 mg/kg every 8 hours, not oral therapy, due to high risk of dissemination and visceral complications. 4, 6

• Kidney transplant recipients with uncomplicated herpes zoster may receive oral acyclovir or valacyclovir, but close monitoring for dissemination is mandatory. 4

• Consider temporary reduction in immunosuppressive medications in patients with disseminated or invasive disease, when clinically feasible. 4

Disseminated or Severe Disease

• Intravenous acyclovir is mandatory for patients presenting with:
  • Lesions in ≥3 dermatomes 4
  • Visceral organ involvement (hepatitis, pneumonia, encephalitis) 4
  • CNS complications (meningitis, encephalitis, Guillain-Barré syndrome) 4
  • Complicated facial/ophthalmic involvement with risk of cranial nerve complications 4
  • Hemorrhagic lesions 4

Renal Dosing Adjustments

• Baseline renal function must be assessed before initiating therapy because acyclovir is eliminated renally and can cause crystalluria and obstructive nephropathy in up to 20% of patients. 4

• Dose adjustments for oral acyclovir 800 mg regimen: 5

  • CrCl >25 mL/min: 800 mg every 4 hours (5 times daily)
  • CrCl 10-25 mL/min: 800 mg every 8 hours
  • CrCl 0-10 mL/min: 800 mg every 12 hours

• Ensure adequate hydration during therapy to minimize risk of crystalluria and nephrotoxicity. 4

Common Pitfalls to Avoid

• Do not delay treatment waiting for laboratory confirmation—diagnosis is clinical in typical presentations and time is critical. 1

• Do not use short-course regimens (1-3 days) designed for genital herpes; these are inadequate for varicella-zoster infection. 4

• Do not use topical antiviral therapy, which is substantially less effective than systemic therapy and is not recommended. 4

• Do not discontinue treatment at exactly 7 days if lesions are still forming or have not completely scabbed—continue until all lesions have crusted. 4

• Do not use the 400 mg three-times-daily dose; this is only appropriate for genital herpes or HSV suppression, not shingles. 4

Monitoring for Treatment Failure

• If lesions have not begun to resolve within 7-10 days of appropriate therapy, suspect acyclovir resistance and obtain viral culture with susceptibility testing. 4

• Acyclovir resistance is rare in immunocompetent patients but occurs in up to 7% of immunocompromised patients, particularly those on prolonged suppressive therapy. 4

• For confirmed acyclovir-resistant VZV, switch to foscarnet 40 mg/kg IV every 8 hours until clinical resolution. 4

What Oral Acyclovir Accomplishes

• Significantly reduces time to last new lesion formation, loss of vesicles, and full crusting when started within 48-72 hours. 2, 3

• Reduces acute pain severity during the active phase of disease, with 40% of patients with severe pain on entry having no or only mild pain at end of treatment versus 0% in placebo groups. 3

• Does NOT significantly reduce the frequency or severity of postherpetic neuralgia in most studies, though it may modestly reduce duration of zoster-associated pain. 6, 2, 8

• Antiviral medications do not eradicate latent virus but help control symptoms and reduce complications during acute infection. 4